JP2010513300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513300A5 JP2010513300A5 JP2009541572A JP2009541572A JP2010513300A5 JP 2010513300 A5 JP2010513300 A5 JP 2010513300A5 JP 2009541572 A JP2009541572 A JP 2009541572A JP 2009541572 A JP2009541572 A JP 2009541572A JP 2010513300 A5 JP2010513300 A5 JP 2010513300A5
- Authority
- JP
- Japan
- Prior art keywords
- obese patients
- bmi
- pharmaceutically acceptable
- use according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020772 Hypertension Diseases 0.000 claims description 8
- 239000002461 renin inhibitor Substances 0.000 claims description 8
- 229940086526 renin-inhibitors Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000002934 diuretic Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001882 diuretic effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims 2
- 229960002003 hydrochlorothiazide Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87018006P | 2006-12-15 | 2006-12-15 | |
| PCT/US2007/087322 WO2008074001A1 (en) | 2006-12-15 | 2007-12-13 | Renin inhibitors for the prevention and treatment of hypertension in obese patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010513300A JP2010513300A (ja) | 2010-04-30 |
| JP2010513300A5 true JP2010513300A5 (enExample) | 2011-02-03 |
Family
ID=39186152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009541572A Withdrawn JP2010513300A (ja) | 2006-12-15 | 2007-12-13 | 肥満患者における高血圧の予防および処置のためのレニン阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100029775A1 (enExample) |
| EP (1) | EP2094259A1 (enExample) |
| JP (1) | JP2010513300A (enExample) |
| KR (1) | KR20090090384A (enExample) |
| CN (1) | CN101583355A (enExample) |
| AU (1) | AU2007333095B2 (enExample) |
| BR (1) | BRPI0721167A2 (enExample) |
| CA (1) | CA2672579A1 (enExample) |
| CL (1) | CL2007003628A1 (enExample) |
| IL (1) | IL198876A0 (enExample) |
| MA (1) | MA31003B1 (enExample) |
| MX (1) | MX2009006340A (enExample) |
| NO (1) | NO20092597L (enExample) |
| RU (1) | RU2009126741A (enExample) |
| TN (1) | TN2009000240A1 (enExample) |
| TW (1) | TW200831071A (enExample) |
| WO (1) | WO2008074001A1 (enExample) |
| ZA (1) | ZA200903442B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2143425A1 (de) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Direktverpresste Aliskiren-Tabletten |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| AR047880A1 (es) * | 2004-02-17 | 2006-03-01 | Novartis Ag | COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS |
| NZ549535A (en) * | 2004-03-17 | 2010-11-26 | Novartis Ag | Use of aliskiren for treating renal and other disorders |
| WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
| CA2655144A1 (en) * | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
-
2007
- 2007-12-13 US US12/519,189 patent/US20100029775A1/en not_active Abandoned
- 2007-12-13 CN CNA2007800499179A patent/CN101583355A/zh active Pending
- 2007-12-13 AU AU2007333095A patent/AU2007333095B2/en not_active Ceased
- 2007-12-13 RU RU2009126741/15A patent/RU2009126741A/ru not_active Application Discontinuation
- 2007-12-13 EP EP07865611A patent/EP2094259A1/en not_active Withdrawn
- 2007-12-13 WO PCT/US2007/087322 patent/WO2008074001A1/en not_active Ceased
- 2007-12-13 CA CA002672579A patent/CA2672579A1/en not_active Abandoned
- 2007-12-13 KR KR1020097014655A patent/KR20090090384A/ko not_active Withdrawn
- 2007-12-13 MX MX2009006340A patent/MX2009006340A/es not_active Application Discontinuation
- 2007-12-13 BR BRPI0721167-8A patent/BRPI0721167A2/pt not_active IP Right Cessation
- 2007-12-13 JP JP2009541572A patent/JP2010513300A/ja not_active Withdrawn
- 2007-12-14 TW TW096148110A patent/TW200831071A/zh unknown
- 2007-12-14 CL CL200703628A patent/CL2007003628A1/es unknown
-
2009
- 2009-05-19 ZA ZA200903442A patent/ZA200903442B/xx unknown
- 2009-05-21 IL IL198876A patent/IL198876A0/en unknown
- 2009-06-12 TN TNP2009000240A patent/TN2009000240A1/fr unknown
- 2009-06-17 MA MA32007A patent/MA31003B1/fr unknown
- 2009-07-08 NO NO20092597A patent/NO20092597L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Atlas | The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition | |
| Probstfield et al. | Progression of cardiovascular damage: the role of renin–angiotensin system blockade | |
| ME00479B (me) | Lijek za profilaksu i tretman arterioskleroze i hipertenzije | |
| KR20050008717A (ko) | 레닌 억제제, 칼슘 채널 차단제 및 이뇨제를 포함하는약제학적 조성물 | |
| EP3027183B1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| JP2023546970A5 (enExample) | ||
| WO2000066104A9 (en) | Ace-2 inhibiting compounds and methods of use thereof | |
| JP2012046531A (ja) | 医薬組合せ剤 | |
| JP2010513300A5 (enExample) | ||
| CN106163518B (zh) | 包含血管紧张素-Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的药物组合制剂 | |
| Meredith | Candesartan cilexetil–a review of effects on cardiovascular complications in hypertension and chronic heart failure | |
| Van Zwieten | Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences | |
| JP2001517698A (ja) | 腎移植患者の生存率を増大させる薬剤の製造のためのアンギオテンシンｉｉ受容体アンタゴニストの使用 | |
| Dodson | Hypertension and diabetes | |
| TWI354553B (en) | Drug for glomerular diseases | |
| JPWO2011162390A1 (ja) | 徐放性高血圧および腎機能障害治療剤 | |
| TW201000097A (en) | Medicament for the prophylaxis or treament of hypertension | |
| IL276474B2 (en) | Modified bisphenyl butanoic ester derivatives as nep inhibitors | |
| US20120088730A1 (en) | Use of angiotensin converting enzyme (ace) domain specific inhibitors to inhibit or enhance cytokine production and alter immune response | |
| WO2003007964A1 (en) | Remedial or preventive agent for cardiopathy or aneurysm containing chymase inhibitory compound | |
| CN110215455A (zh) | 一种用于降血压的药物配方 | |
| Chaabouni et al. | ALDOSTERONE IN POLYCYSTIC OVARY SYNDROME | |
| Galceran et al. | Renin Angiotensin System and Obesity-Related Organ Damage | |
| Saez et al. | The renin inhibitor aliskiren as novel treatment for cardiovascular disease | |
| Mirkabilovich et al. | The effectiveness of ACE inhibitors and sartans patients with acute myocardial infarction in the elderly on a distant stage monitoring |